Spots Global Cancer Trial Database for Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Official Title: A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Study ID: NCT05519449
Interventions
Study Description
Brief Summary: This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 administered as a single agent in adults with metastatic castration-resistant prostate cancer (mCRPC).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
UCLA Department of Medicine - Hematology/Oncology, Los Angeles, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Yale New Haven Hospital, New Haven, Connecticut, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Oregon Health and Science University, Portland, Oregon, United States
Sarah Cannon Research, Nashville, Tennessee, United States
Mary Crowley Cancer Research, Dallas, Texas, United States
Chris O'Brien Lifehouse (COBLH), Camperdown, New South Wales, Australia
Southern Oncology Clinical Research Unit (SoCRU), Bedford Park, South Australia, Australia
Linear Clinical Research Ltd., Nedlands, Western Australia, Australia
Contact Details
Name: Janux Therapeutics, MD
Affiliation: Janux Therapeutics
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
